Takahashi, Maiko

写真a

Affiliation

School of Medicine, Cancer Center (Shinanomachi)

Position

Research Associate/Assistant Professor/Instructor

External Links

 

Research Areas 【 Display / hide

  • General surgery

 

Papers 【 Display / hide

  • A case of rapidly grown giant pilomatricoma

    Honda Aki, Funakoshi Takeru, Takahashi Maiko, Kameyama Kaori, Tanese Keiji

    Dermatologica Sinica  2017

    ISSN  1027-8117

  • A randomized controlled study comparing a vessel sealing system with the conventional technique in axillary lymph node dissection for primary breast cancer

    Seki Tomoko, Hayashida Tetsu, Takahashi Maiko, Jinno Hiromitsu, Kitagawa Yuko

    SpringerPlus 5 ( 1 )  2016.12

    ISSN  2193-1801

     View Summary

    <p>Objective: This study aimed to compare the efficacy and safety of the newest bipolar vessel sealing system (BVSS; LigaSure™ Small Jaw) to that of conventional technique in axillary dissection. Methods: Sixty-one patients with breast cancer were randomized to a conventional dissection surgical technique (CONV group; n = 30) by scalpel and monopolar cautery or that using a vessel sealing system (BVSS group; n = 31). Results: There was a significant difference between both groups in the mean number of days until drain removal (6.4 ± 2.9 vs. 8.2 ± 3.8 days; P value = 0.033), and the mean total volume of drainage fluid (365.3 ± 242.2 vs. 625.1 ± 446.6 mL; P value = 0.009). The incidence of seroma was similar in both groups (43.3 vs. 37.9 %; P value = 0.673). There was no statistically significant difference in axillary dissection operating time (66 vs. 70 min; P value = 0.371), or the mean volume of blood loss (18.2 ± 31.1 vs. 20.6 ± 26.3 mL; P value = 0.663). Conclusions: Our results suggest that BVSS is a more effective device when compared to the conventional techniques in axillary dissection.</p>

  • Biological markers of invasive breast cancer

    Matsumoto Akiko, Jinno Hiromitsu, Ando Tomofumi, Fujii Taku, Nakamura Tetsuya, Saito Junichi, Takahashi Maiko, Hayashida Tetsu, Kitagawa Yuko

    Japanese Journal of Clinical Oncology 46 ( 2 ) 99 - 105 2016.02

    ISSN  0368-2811

     View Summary

    <p>Biological markers for breast cancer are biomolecules that result from cancer-related processes and are associated with particular clinical outcomes; they thus help predict responses to therapy. In recent years, gene expression profiling has made themolecular classification of breast cancer possible. Classification of breast cancer by immunohistochemical expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 and Ki-67 is standard practice for clinical decision- making. Assessments of hormone receptor expression and human epidermal growth factor receptor 2 overexpression help estimate benefits from targeted therapies and have greatly improved prognoses for women with these breast cancer types. Although Ki-67 positivity is associated with an adverse outcome, its clear identification is an aid to optimal disease management. Standardization of testingmethodology to minimize inter-laboratory measurement variations is a remaining issue.Multigene assays provide prognostic information and identify those most likely to benefit from systemic chemotherapy. Incorporating molecular profiles with conventional pathological classification would bemore precise, and could enhance the clinical development of personalized therapy in breast cancer.</p>

  • Technical feasibility of sentinel lymph node biopsy in patients with ipsilateral breast tumor recurrence and previous axillary surgery

    Matsumoto Akiko, Jinno Hiromitsu, Nakamura Tetsuya, Saito Junichi, Takahashi Maiko, Hayashida Tetsu, Kameyama Kaori, Kitagawa Yuko

    International Journal of Surgery 22   28 - 31 2015.10

    ISSN  1743-9191

     View Summary

    <p>Introduction: The role of sentinel lymph node biopsy (SLNB) in patients with ipsilateral breast tumor recurrence (IBTR) remains to be elucidated. The aim of this study was to evaluate feasibility and validity of SLNB in patients with IBTR. Methods: A prospective database of 1172 patients with clinically node-negative breast cancer who underwent SLNB from January 2005 to December 2013 at Keio University Hospital was analyzed and 35 patients with IBTR underwent SLNB. Sentinel lymph nodes (SLNs) were detected using a combined method of blue dye and radioisotope or indocyanine green fluorescence in cases with failure of identification by blue dye and radioisotope. Results: Twenty-two patients had previous SLNB, eight had previous axillary lymph node dissection (ALND), and five had no previous axillary surgery. Overall, SLNs were successfully identified in 28 (80.0%) of 35 patients. The identification rate in patients with previous SLNB, ALND and no axillary surgery was 81.8% (18/22), 75% (6/8) and 80% (4/5), respectively (P = 0.52). Aberrant drainage outside the ipsilateral axilla was found more frequently in patients with previous ALND compared with SLNB and no axillary treatment (37.5% vs. 4.5% vs. 0%, P = 0.048). No axillary recurrence was observed after median follow-up of 40.3 months from the second surgery for IBTR. Conclusions: SLNB is a technically feasible and valid procedure for staging and treatment of regional lymph nodes in patients with IBTR.</p>

  • Registration and projection method of tumor region projection for breast cancer surgery

    Kanegae Motoko, Morita Jun, Shimamura Sho, Uema Yuji, Takahashi Maiko, Inami Masahiko, Hayashida Tetsu, Sugimoto Maki

      201 - 202 2015.08

     View Summary

    <p>This paper introduces a registration and projection method for directly projecting the tumor region for breast cancer surgery assistance based on the breast procedure of our collaborating doctor. We investigated the steps of the breast cancer procedure of our collaborating doctor and how it can be applied for tumor region projection. We propose a novel way of MRI acquisition so we may correlate the MRI coordinates to the patient in the real world. By calculating the transformation matrix from the MRI coordinates and the coordinates from the markers that is on the patient, we are able to register the acquired MRI data to the patient. Our registration and presentation method of the tumor region was then evaluated by medical doctors.</p>

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 乳癌におけるHOXB9スプライスバリアントの探求

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 髙橋 麻衣子, Grant-in-Aid for Scientific Research (C), Principal Investigator

  • 乳癌転移巣ER遺伝子変異とCDK4/6阻害剤の相関検討と効果予測法の確立

    2016.04
    -
    2019.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 高橋 麻衣子, Grant-in-Aid for Scientific Research (C), Principal Investigator